These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35815435)

  • 1. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
    Carey N; Leahy J; Trela-Larsen L; McCullagh L; Barry M
    Int J Technol Assess Health Care; 2022 Jul; 38(1):e56. PubMed ID: 35815435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.
    Carey N; Leahy J; Trela-Larsen L; Mc Cullagh L; Barry M
    J Mark Access Health Policy; 2023; 11(1):2166375. PubMed ID: 36684853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
    Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
    Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Sep; 22(5):749-765. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.
    Gye A; Goodall S; De Abreu Lourenco R
    Pharmacoeconomics; 2023 Feb; 41(2):175-186. PubMed ID: 36266557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
    McCullagh L; Walsh C; Barry M
    Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
    Andrade AM; Teixeira VR; Pogue R; Figueiredo ACMG; Carvalho JL
    Cytotherapy; 2023 Sep; 25(9):930-938. PubMed ID: 37341664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective.
    Wang XJ; Wang YH; Ong MJC; Gkitzia C; Soh SY; Hwang WYK
    Clinicoecon Outcomes Res; 2022; 14():333-355. PubMed ID: 35535300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Sarkar RR; Gloude NJ; Schiff D; Murphy JD
    J Natl Cancer Inst; 2019 Jul; 111(7):719-726. PubMed ID: 30551196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
    Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
    Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
    Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
    J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.